Trial Profile
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. A GERCOR Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TEXCAN
- 27 Apr 2022 Results published in the European Journal of Cancer
- 04 Jun 2019 Results assessing the correlations between OS and concentrations of regorafenib and its active metabolites M-2 and M-5, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 13 May 2019 According to a Bayer media release, data from this study will be presented in the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago, Illinois (USA).